Adenosine A2A receptor antagonists for treating and preventing hepatic fibrosis, cirrhosis and fatty liver

摘要

Hepatic cirrhosis and fibrosis and fatty liver can be prevented and treated by administering to a subject in need thereof an effective amount of at least one adenosine A2A receptor antagonist or at least one adenosine uptake promotor.